Clinical Implications of COVID-19-Related Endothelial Dysfunction.

Autor:	Aljadah M; Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Khan N; Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Beyer AM; Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Chen Y; Division of Endocrinology and Molecular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.; Versiti Blood Center of Wisconsin, Milwaukee, Wisconsin, USA., Blanker A; Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Widlansky ME; Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Jazyk:	angličtina
Zdroj:	JACC. Advances [JACC Adv] 2024 Jul 03; Vol. 3 (8), pp. 101070. Date of Electronic Publication: 2024 Jul 03 (Print Publication: 2024).
DOI:	10.1016/j.jacadv.2024.101070
Abstrakt:	Endothelial dysfunction represents a measurable and early manifestation of vascular disease. Emerging evidence suggests cardiovascular risk remains elevated after COVID-19 infection for at least 12 months, regardless of cardiovascular disease status prior to infection. We review the relationship between the severity of endothelial dysfunction and the severity of acute COVID-19 illness, the degree of impairment following recovery in both those with and without postacute sequalae SARS-CoV-2 infection, and current therapeutic efforts targeting endothelial function in patients following COVID-19 infection. We identify gaps in the literature to highlight specific areas where clinical research efforts hold promise for progress in understanding the connections between endothelial function, COVID-19, and clinical outcomes that will lead to beneficial therapeutics. Competing Interests: Dr Widlansky is funded by HL144098, HL173778, K24HL152143, R38HL143561, R38HL167238, AHA9639561, and AHA847970. Dr Beyer is supported by HL157025, HL173549, AHA9639561, and AHA847970. Dr Chen is supported by HL164460. Dr Aljadah is supported by R38HL143561. Drs Beyer, Chen, and Widlansky are recipients of a grant from the 10.13039/100000968American Heart Association to study the effect of probiotic supplementation (AHA9639591) on patients with postacute sequelae of COVID-19. For that study, the probiotic supplement is supplied by Probi (based in Lund, Sweden). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu